Does UnitedHealthcare Cover Finasteride?

How UnitedHealthcare Formularies Work for Finasteride

UnitedHealthcare assigns finasteride to Tier 2 or Tier 3 on most commercial formularies, meaning members pay a mid-range to higher copay rather than the lowest generic cost-sharing tier. The exact tier depends on which UHC plan you hold. UHC administers dozens of distinct formularies across its commercial, Medicare Advantage, and Medicaid lines, so the tier for generic finasteride 1 mg can differ between a UHC Choice Plus PPO and a UHC Manage HMO even within the same state.

Finasteride received FDA approval for 5 mg daily in benign prostatic hyperplasia (BPH) in 1992, and the 1 mg dose for androgenetic alopecia (male pattern hair loss) in 1997 [1]. Both indications appear on UHC formularies, but the BPH indication (5 mg) tends to face fewer prior-authorization hurdles because BPH is classified as a medical condition rather than cosmetic hair restoration. The FDA label specifies that finasteride 1 mg is indicated only in men; the label explicitly states the drug should not be used by women of childbearing potential because of risk of fetal harm [1].

Generic finasteride became widely available after 2006, driving cash-pay prices well below $20 per month at most national pharmacy chains [2]. That price reality matters: even when UHC denies a prior-authorization request, a GoodRx or pharmacy discount card often brings out-of-pocket cost below the Tier 3 copay. Kaufman et al. (J Am Acad Dermatol, 1998; N=879) demonstrated that finasteride 1 mg produced statistically significant hair count increases versus placebo at 48 weeks (P<0.001), establishing the efficacy foundation that supports its formulary inclusion today [3].

The UHC commercial drug list is publicly searchable at the UHC website pharmacy tool. Entering the drug name and your plan name reveals the current tier assignment and any attached utilization management requirements before you ask your prescriber to submit a request.

Prior Authorization Criteria for Finasteride on UHC Plans

Prior authorization for finasteride 1 mg on UnitedHealthcare commercial plans is common and rated moderate in difficulty. Meeting the criteria typically means satisfying three conditions documented in the clinical notes. First, the prescriber must confirm a diagnosis of androgenetic alopecia in a male patient, supported by clinical examination. Second, the patient must not have a contraindication to 5-alpha reductase inhibitors, including a history of hypersensitivity or, in older patients, certain prostate cancer screening considerations [4]. Third, for some plan variants, the member must have completed a documented trial of topical minoxidil (commonly 3 months at 5% concentration) without adequate response before finasteride is approved.

The FDA Safety Communication from 2012 added a requirement to the finasteride label noting possible persistent sexual side effects after discontinuation in a subset of users [5]. UHC prior-authorization reviewers may ask whether the prescriber discussed these risks, particularly depression and sexual dysfunction, with the patient. Having a visit note that documents informed consent for these risks can prevent a supplemental information request that delays the approval clock.

Finasteride 5 mg for BPH typically bypasses the cosmetic-indication scrutiny. The American Urological Association (AUA) 2021 guideline on benign prostatic hyperplasia recommends 5-alpha reductase inhibitors, including finasteride, for men with bothersome lower urinary tract symptoms and enlarged prostate volume, which gives prescribers a strong guideline anchor for the PA narrative [6]. Citing the AUA guideline directly in the PA submission reduces the chance of an initial denial.

Processing time under UHC's standard PA pathway is up to 15 calendar days for non-urgent requests, or 72 hours for urgent clinical situations, as required by most state insurance regulations and the federal Mental Health Parity and Addiction Equity Act framework. If you have not received a decision within that window, a follow-up call to the UHC pharmacy PA line (number on your member ID card) is appropriate.

Does UHC Require Step Therapy Before Approving Finasteride?

Step therapy applies to the 1 mg hair-loss indication on select UHC commercial plans. The required first-step agent is almost always topical minoxidil 5%, which is available over the counter without a prescription [7]. The step requirement exists because minoxidil carries a lower cost to the plan and has FDA clearance for androgenetic alopecia as well [8].

A documented minoxidil trial of at least 90 days is what UHC clinical reviewers typically look for. Shorter trials may be rejected. The prescriber's chart note should record the start date, concentration used (2% or 5%), patient adherence, and the specific response observed, whether that means no new growth, worsening shedding, or intolerable scalp irritation. Scalp irritation from propylene glycol in minoxidil formulations is a legitimate documented reason to skip the step-therapy requirement through a step-therapy exception request [9].

Several states have enacted step-therapy reform laws that limit insurers' ability to require step therapy when a prescriber certifies a clinical exception. As of 2024, more than 30 states have such statutes [10]. If your state has a step-therapy exception law and your prescriber submits a written exception citing clinical necessity or prior treatment failure, UHC is generally obligated to respond within the mandated state timeline, often 72 hours for urgent and 14 days for standard requests.

What Finasteride Costs Under UHC vs. Cash Pay

At Tier 3 on a typical UHC commercial plan, finasteride 1 mg costs members roughly $30 to $60 per 30-day supply depending on the specific plan's cost-sharing design and deductible status. Before the deductible is met, the member pays the negotiated rate, which can be higher. The brand-name product Propecia carries a manufacturer list price near $85 per month; very few plans cover brand Propecia when generic is available, so brand coverage is rarely the relevant question [2].

Generic finasteride 1 mg at major national pharmacies using GoodRx or a similar discount card runs approximately $10 to $15 per 30-day supply as of 2025 [2]. That is a material difference. A member who cannot secure PA approval and whose annual deductible has not reset may find cash pay cheaper than running the claim through insurance. Finasteride 5 mg for BPH is similarly priced: roughly $10 to $18 per 30-day supply at generic-friendly pharmacies.

The Merck patient assistance program historically provided Propecia at reduced cost to qualifying uninsured patients, but generic availability has effectively replaced most manufacturer assistance program utility for this drug. Manufacturer savings cards for branded Propecia are generally restricted by terms that exclude patients using government-funded insurance (Medicare, Medicaid, TRICARE). Commercially insured UHC members may technically use a savings card for brand if their plan covers brand and the card terms permit, but this scenario is uncommon given generic substitution policies [11].

How to Appeal a UHC Denial of Finasteride

UnitedHealthcare's appeal process follows a two-level internal structure, then an external independent review organization (IRO) if internal appeals fail. The first-level internal appeal must be filed within 180 days of the denial notice under the ACA appeals framework [12]. For a finasteride PA denial, the appeal packet should include the original denial letter, the prescriber's clinical note with the diagnosis, any evidence of prior minoxidil failure (dates, concentrations, results), relevant peer-reviewed literature, and a letter of medical necessity signed by the treating physician.

For the hair-loss indication, citing Kaufman et al. (1998) [3] and the American Academy of Dermatology (AAD) guidelines, which list finasteride as a first-line treatment for male androgenetic alopecia, strengthens the medical necessity argument [13]. The AAD position statement notes that finasteride 1 mg daily is among the most effective pharmacologic treatments available for male pattern hair loss. Quoting guideline language verbatim in the appeal letter often carries more weight than a paraphrased summary.

Second-level internal appeals at UHC are reviewed by a different clinical reviewer than the first level. If the second-level appeal is denied, the member has the right to request external review through a state-certified IRO within 4 months of the final internal denial, or 60 days, whichever is greater, depending on state law [12]. External IRO decisions are binding on the insurer in most states. Published data on external review outcomes for dermatologic drug denials show overturn rates between 30% and 50% at the IRO stage, meaning the process is worth pursuing [14].

Patients who believe a denial is based on a cosmetic-exclusion clause should request the specific policy language UHC cited. If the prescriber documented that androgenetic alopecia is causing psychological distress, some plans' cosmetic-exclusion language may not apply, particularly when the plan includes mental health parity protections under the Mental Health Parity and Addiction Equity Act (MHPAEA) [15].

Finasteride for Women: Coverage Considerations

Finasteride is not FDA-approved for use in women. The FDA label for finasteride 1 mg and 5 mg explicitly contraindicates use in women of childbearing potential due to teratogenicity risk, specifically Type II 5-alpha reductase inhibition that can cause ambiguous genitalia in a male fetus [1]. Off-label use in postmenopausal women with androgenetic alopecia exists in clinical practice; a small randomized trial (N=36) published in the Journal of the American Academy of Dermatology found 1 mg daily produced modest benefit in postmenopausal women over 12 months [16]. However, UHC and most commercial insurers will deny coverage for finasteride in women because of the off-label status combined with the FDA contraindication language, and appeals on this basis face significant resistance [17].

Prescribers pursuing off-label use in postmenopausal women should document the clinical rationale thoroughly, note that the patient is postmenopausal (eliminating the teratogenicity concern), and reference the published trial data [16]. Even with strong documentation, cash pay at roughly $12 per month is usually more practical than exhausting the appeals process for this indication.

Finasteride and UHC Medicare Advantage Plans

Medicare Part D formularies follow CMS star-rating and formulary guidelines that differ from commercial plan rules. Generic finasteride appears on many Medicare Part D formularies at Tier 1 or Tier 2 because of its age and generic availability. However, Medicare coverage policy excludes drugs used for cosmetic purposes under 42 U.S.C. 1395w-102(e), which means finasteride prescribed for hair loss is explicitly excluded from Part D coverage regardless of formulary tier [18]. Finasteride 5 mg for BPH does not face this exclusion and is generally covered under Medicare Part D at a low generic copay [18].

UHC Medicare Advantage members should confirm the BPH indication is clearly documented on the prescription. A prescription written with a diagnosis code for androgenetic alopecia on a Medicare plan will trigger automatic rejection, while the same drug with a BPH diagnosis code will typically process without issue.

Getting Your Prescriber to Submit an Effective PA Request

The single most common reason PA requests fail at the initial submission stage is incomplete clinical documentation. The prescriber's office submits a standard form without a supporting letter of medical necessity, and the reviewer applies a default denial. Providing your prescriber's office with a brief written summary of the clinical facts, including your diagnosis date, any prior treatments tried, and the relevant guideline references, meaningfully improves first-pass approval rates.

Three elements should appear in every finasteride PA submission to UHC. The diagnosis must match an FDA-approved indication (for commercial plans). Evidence of prior minoxidil trial or a documented clinical exception to step therapy must be present. A statement confirming the prescriber discussed the FDA-required risk information with the patient, including the 2012 safety label update on persistent sexual side effects, should also be included [5]. Missing any one of these three elements is the most common reason for an avoidable denial.

Turnaround time for PA decisions at UHC runs 3 to 15 business days under standard review. Urgent PA requests for BPH in patients with acute urinary retention can be processed in 24 to 72 hours when marked urgent by the prescriber with clinical justification [6].